It is necessary to analyse the diversity of TCR and MHC molecules and their interactions in order to achieve a personalised and beneficial immunotherapeutic treatment for each type of cancer, as it has been shown that the basal diversity of TCR in peripheral blood is associated with clinical outcomes [294,339]. Here, HLA-C is linked to cancer.